← Oncology Approval Tracker

FDA DECISION ·

Retevmo tablets

selpercatinib · Eli Lilly

FDA approvalNew formulationRET-altered lung, thyroid and other solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Tablet presentation for then-labeled RET-altered cancers, including adult RET fusion-positive locally advanced or metastatic non-small cell lung cancer, qualifying RET-altered medullary or other thyroid cancers from age 12, and qualifying adult RET fusion-positive solid tumors.

LAMPGEN ANALYSIS

Why it matters

The tablet approval added a different presentation of the RET inhibitor before subsequent 2024 pediatric expansions.

What research teams should watch

Check which dosage form and strengths are being used, and apply the label appropriate to the patient and decision date.

PRIMARY RECORDS

Sources